Fig. 5From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysisScatterplot of probabilistic sensitivity analysis for all randomized patients. A All randomized patients, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatin, WTP Willingness to pay, QALY Quality-adjusted life yearBack to article page